Ling Weiping, Paterson David L, Harris Patrick N A, Furuya-Kanamori Luis, Edwards Felicity, Laupland Kevin B
Faculty of Medicine, UQ Centre for Clinical Research, University of Queensland, Herston, Brisbane, Australia.
ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
Open Forum Infect Dis. 2023 Feb 10;10(3):ofad071. doi: 10.1093/ofid/ofad071. eCollection 2023 Mar.
There is increasing morbidity and mortality attributed to escalating incidence of bloodstream infection (BSI). The epidemiology of BSI is dynamic and differs across populations. This study aimed to describe this epidemiology in Queensland, Australia.
Incident BSIs (new or recurring ≥30 days from previous BSI) in adult (≥15 years) Queenslanders were identified from 2000 to 2019 using Queensland Health databases. Incidence rates, crude and standardized by age and gender, were calculated. Negative binomial regressions were performed to determine predictors of BSI incidence.
From 2000 to 2019, 30 350 BSIs in 27 793 patients were detected; the standardized incidence rate almost doubled from 34.1 to 65.9 cases per 100 000 residents. Predictors of higher incidence rate were older age (≥65 years), comorbidity, and community-onset infection. Despite holding these factors constant, the incidence rate was estimated to increase 4% (adjusted incidence rate ratio [IRR], 1.04; 95% CI, 1.03-1.04) annually over the study period. Approximately 4.2% of isolates produced extended-spectrum beta-lactamase (ESBL-Ec), with most (95%) detected after 2010. The incidence rate of ESBL-Ec increased 25% (IRR, 1.25%; 95% CI, 1.2-1.3) annually, significantly faster than that of non-producers. Amikacin and carbapenems remain effective in vitro against ESBL-Ec BSI in Queensland.
The rise in BSIs is driven both by a higher infection rate and shifting epidemiology toward community-onset infections. These are likely attributed to an aging Australian population with increasing chronic comorbidity. The rapid expansion of ESBL-Ec in recent years is concerning and should be acknowledged for its implication in the community.
血流感染(BSI)发病率不断上升,导致发病和死亡人数日益增加。BSI的流行病学情况动态变化,因人群而异。本研究旨在描述澳大利亚昆士兰州的这种流行病学情况。
利用昆士兰州卫生数据库,确定2000年至2019年昆士兰州15岁及以上成年人中的新发BSI(新发病例或距上次BSI发作≥30天的复发病例)。计算发病率,包括粗发病率以及按年龄和性别标准化后的发病率。进行负二项回归以确定BSI发病率的预测因素。
2000年至2019年,共检测到27793例患者发生30350例BSI;标准化发病率从每10万居民34.1例几乎翻倍至65.9例。发病率较高的预测因素为老年(≥65岁)、合并症和社区获得性感染。尽管保持这些因素不变,但在研究期间,发病率估计每年增加4%(调整后的发病率比[IRR],1.04;95%置信区间,1.03 - 1.04)。约4.2%的分离株产生超广谱β-内酰胺酶(ESBL-Ec),其中大部分(95%)在2010年后被检测到。ESBL-Ec的发病率每年增加25%(IRR,1.25%;95%置信区间,1.2 - 1.3),显著快于非产ESBL-Ec菌株。阿米卡星和碳青霉烯类药物在体外对昆士兰州的ESBL-Ec BSI仍有效。
BSI的增加既归因于感染率上升,也归因于流行病学向社区获得性感染的转变。这可能归因于澳大利亚人口老龄化以及慢性合并症增加。近年来ESBL-Ec的迅速传播令人担忧,因其在社区中的影响应得到重视。